The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
Quetiapine versus other atypical antipsychotics for schizophrenia
Open accessAbstract
BACKGROUND: In many countries of the industrialised world second generation ('atypical') antipsychotic drugs have become the first line drug treatment for people with schizophrenia. It is not clear how the effects of the various second generation antipsychotic drugs differ. OBJECTIVES: To evaluate the effects of quetiapine compared with other second generation antipsychotic drugs for people with schizophrenia and schizophrenia-like psychosis. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group Trials Register (April 2007), inspected references of all identified studies, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised control trials comparing oral quetiapine with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. For continuous data, we calculated weighted mean differences (WMD) again based on a random-effects model. MAIN RESULTS: The review currently includes 21 randomised control trials (RCTs) with 4101 participants. These trials provided data on four comparisons - quetiapine versus clozapine, olanzapine, risperidone or ziprasidone.A major limitation to all findings is the high number of participants leaving studies prematurely (57.6%) and the substantial risk of biases in studies. Efficacy data favoured olanzapine and risperidone compared with quetiapine (PANSS total score versus olanzapine:10 RCTs, n=1449, WMD 3.66 CI 1.93 to 5.39; versus risperidone: 9 RCTs, n=1953, WMD 3.09 CI 1.01 to 5.16), but clinical meaning is unclear. There were no clear mental state differences when quetiapine was compared with clozapine or ziprasidone.Compared with olanzapine, quetiapine produced slightly fewer movement disorders (6 RCTs, n=1090, RR use of antiparkinson medication 0.49 CI 0.3 to 0.79, NNH 25 CI 14 to 100) and less weight gain (7 RCTs, n=1173, WMD -2.81 CI -4.38 to -1.24) and glucose elevation, but more QTc prolongation (3 RCTs, n=643, WMD 4.81 CI 0.34 to 9.28). Compared with risperidone, quetiapine induced slightly fewer movement disorders (6 RCTs, n=1715, RR use of antiparkinson medication 0.5 CI 0.3 to 0.86, NNH 20 CI 10 to 100), less prolactin increase (6 RCTs, n=1731, WMD -35.28 CI -44.36 to -26.19) and some related adverse effects, but more cholesterol increase (5 RCTs, n=1433, WMD 8.61 CI 4.66 to 12.56). Compared with ziprasidone, quetiapine induced slightly fewer extrapyramidal adverse effects (1 RCT, n=522, RR use of antiparkinson medication 0.43 CI 0.2 to 0.93, NNH not estimable) and prolactin increase. On the other hand quetiapine was more sedating and led to more weight gain (2 RCTs, n=754, RR 2.22 CI 1.35 to 3.63, NNH 13 CI 8 to 33) and cholesterol increase than ziprasidone. AUTHORS' CONCLUSIONS: Best available evidence from trials suggests that most people who start quetiapine stop taking it within a few weeks. Comparisons with amisulpride, aripiprazole, sertindole and zotepine do not exist. Most data that has been reported within existing comparisons are of very limited value because of assumptions and biases within them. There is much scope for further research into the effects of this widely used drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–223 of 223
Peluso, M. J., Lewis, S. W., Barnes, T. R. E., & Jones, P. B. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2012.12.008 · Cited by 13
Luca, V. D., VINCENT, J., Müller, D., Hwang, R., Shinkai, T., Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J., & Citrome, L. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.10.013 · Cited by 10
D2 Receptor occupancy in risperidone and clozapine-treated schizophrenics
Su, T.-P., Breier, A. F., Coppola, R., Hadd, K., Elman, I., Adler, C. M., Malhotra, A. K., Watsky, E. J., Gorey, J. G., Weinberger, D. R., et al. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(96)84000-5 · Cited by 9
Bitter, I., Brook, S., Dossenbach, M. R. K., et al. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)80346-0 · Cited by 7
Extrapyramidal side effects of risperidone
Jinan, P. (2000) · Cited by 6
Comparison of efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia
Liu, G., 赵振环, 刘国雄, 蔡广惠, 黄金满, 李英, & 蔡颖莲 (2005) · Zhonghua xingwei yixue yu naokexue zazhi · doi:10.3760/cma.j.issn.1005-8559.2005.08.017 · Cited by 6
Dopamine2- and serotonine2-receptor-antagonism by antipsychotics in man
Louwerens, J. W., Slooff, C. J., Korf, J., Coppens, H., & Paans, A. M. J. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(96)85465-x · Cited by 5
Chen, Q. (2005) · Zhonghua xingwei yixue yu naokexue zazhi · Cited by 4
Jun-li, M. (2005) · Zhongguo shenjing jingshen jibing zazhi · Cited by 4
Wang, C. (2005) · Zhongguo xinli weisheng zazhi · Cited by 4
Analysis of the Efficacy of Aripiprazole and Quetiapine in the Treatment of Schizophrenia
Jin-bo, C. (2008) · Zhiye yu jiankang · Cited by 4
A clinical analysis of aripiprazole and quetiapine in treatment of first episode schizophrenia
Xiu-yin, L. (2007) · The Journal of Clinical Psychiatry · Cited by 4
The effects of risperidone and clozapine to patients with schizophrenia's life quality.
Minghu, D. (2003) · Sichuan Mental Health · Cited by 4
Jun-li, M. (2005) · 临床精神医学杂志 · Cited by 3
A Comparative Study Between Quetiapine and Risperidone in the Treatment of Schizophrenia
Heying, L. (2005) · Journal of Heze Medical College · Cited by 3
Assessment of striatal dopamine function in schizophrenia
Breier, A. F., Su, T., Weisenfeld, N., Elman, I., Adler, C. H., Malhotra, A. K., & Pickar, D. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(96)83997-7 · Cited by 2
Cognitive benefits of quetiapine versus risperidone in schizophrenia
Spellmann, I., Riedel, M. J., Müller, N., Strassnig, M., Douhet, A., Dehning, S., & Möller, H. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-918844 · Cited by 2
A control study of olanzapine and ziprasidone in the treatment of adolescent schizophrenia
Geng, S. (2008) · Guide of China Medicine · Cited by 2
Sheng-zhon, W. (2006) · Nervous Diseases and Mental Health · Cited by 2
Comperison of quetiapine and aripiprazole in the treatment of first episode schizophrenia
Bao-f, A. (2008) · The Journal of Clinical Psychiatry · Cited by 2
Qing-xua, L. (2008) · Chinese Medical Journal of Metallurgical Industry · Cited by 2
Yang, L.-Q. (2010) · Medical Journal of Chinese People's Health · Cited by 1
Cited by
Suicide prevention strategies revisited: 10-year systematic review
Zalsman, G., Hawton, K., Wasserman, D., van Heeringen, K., Arensman, E., Sarchiapone, M., Carli, V., Höschl, C., Barzilay, R., Balazs, J., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30030-x · Cited by 1,765
Bang, J., Spina, S., & Miller, B. L. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00461-4 · Cited by 1,144
Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 675
Self-citationHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Metadata
- Authors
- Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2010-01-20
- Issue
- 1
- Pages
- CD006625-CD006625
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2058181488
- Cited by
- 260
- References
- 223
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.